CCND1 and prostate carcinoma: In two of them, the compound caused a decrease in GSK3β phosphorylation: in the human hepatocellular carcinoma cell line Huh-7, it achieved this via PI3K/AKT, also suppressing LiCl-induced activity [92], while in prostate cancer LNCaP and DU145 cells, it also increased protein levels of Axin and reduced levels of target genes cyclin D1 and MMP-2 [93], in both cases leading to a loss of carcinogenicity.